New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2023-11-15 DOI:10.1016/j.tranon.2023.101820

Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter

引用次数: 0

查看原文本刊更多论文

对DLBCL中可能的HDAC抑制剂耐药的新见解——Havas等人对“定义对HDAC选择性抑制剂的细胞反应表明，需要有效靶向HDAC3来引发细胞毒性并克服naïve弥漫性大B细胞淋巴瘤中泛hdaci的耐药”的评论。

摘要不可用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.